Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

Functional Bowel Disorder Clinical Trial

Official title:
Multicenter, Randomized, Parallel-group, Open-label, Comparative Clinical Study to Evaluate Efficacy and Safety of Mebeverine+Simethicone Fixed-dose Combination Versus Duspatalin® (Mebeverine) and Versus Espumisan® (Simethicone) in Patients With Functional Bowel Disorders With Abdominal Pain and Excess Gas Formation

Status Completed

Clinical Trial Summary

The parallel three-group study of efficacy and safety was planned to investigate the reduction in abdominal pain and bloating during treatment with the fixed-dose combination of Mebeverine + Simethicone versus Duspatalin® and Espumisan® as a monotherapy (Protocol No. MESI3001).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05175131
Study type	Interventional
Source	Abbott
Contact
Status	Completed
Phase	Phase 3
Start date	November 27, 2020
Completion date	May 18, 2021

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06290960` - Patient Reported Outcomes Following Cancer of the Rectum
Recruiting	`NCT06338189` - The 5Ad Diet for Functional Bowel Disorders	N/A
Completed	`NCT03694223` - Health Education Delivery Methods for a Low Fermentable Carbohydrate Diet in Patients With Functional Bowel Disorders	N/A
Recruiting	`NCT03823742` - Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?	N/A
Not yet recruiting	`NCT06315179` - Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)